AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
AZN Chart
People also search for
AstraZeneca lung cancer therapy combination shows promise in advanced study
AstraZeneca said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first-line treatment for a type of lung cancer.
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
AstraZeneca PLC American Depositary Shares Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 33,467 | $6.58M | $5.68M | -$900,571.44 | -13.69% |
 Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 1,107 | $217,868.94 | $187,791.48 | -$30,077.46 | -13.81% |
 Curtis Ellergodt Rothschild Investment LLC | 692 | $121,446 | $111,758 | -$9,688 | -7.98% |
 Dodge & Cox Dodge & Cox Funds | 55,949 | $11.03M | $8.87M | -$2.17M | -19.63% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 105,828 | $20.07M | $17.08M | -$2.98M | -14.87% |
AstraZeneca PLC American Depositary Shares (AZN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AstraZeneca PLC American Depositary Shares ever had a stock split?
AstraZeneca PLC American Depositary Shares Profile
| Pharmaceuticals Industry | Healthcare Sector | Pascal Claude Roland Soriot CEO | NASDAQ (NGS) Exchange | G0593M107 CUSIP |
| GB Country | 96,100 Employees | 7 Aug 2026 Last Dividend | 27 Jul 2015 Last Split | - IPO Date |
Overview
AstraZeneca PLC, established as Zeneca Group PLC before its name change in April 1999, is a biopharmaceutical entity recognized for its deep involvement in the health sector. Since its incorporation in 1992, the company has centered its prowess on the discovery, development, management, and commercialization of prescription medicines. Holding its headquarters in Cambridge, United Kingdom, AstraZeneca has expanded its reach globally, touching the markets of the United Kingdom, the Americas, Europe, Asia, Africa, and Australasia. Through a network of distributors and local representative offices, it caters to the essential needs of both primary care and specialty care physicians. Furthermore, AstraZeneca upholds strategic collaboration agreements, such as with Neurimmune AG for the development of NI006, and with BenevolentAI targeting drug discovery in systemic lupus erythematosus, underlining its commitment to healthcare innovation and partnerships to tackle diverse health challenges.
Products and Services
Cardiovascular, Renal, and Metabolism Products: AstraZeneca offers a range of medicines including Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, and Farxiga, designed to address various health concerns within cardiovascular, renal, and metabolic diseases. These pharmaceuticals represent the company's focus on developing treatments that aim to improve patient outcomes in these critical areas of medicine.
Oncology: The company's oncology segment features drugs like Orpathys, Truqap, Zoladex, Faslodex, enhancing its footing in the field with innovative solutions for cancer treatment and management, showcasing AstraZeneca's significant contributions to advancing cancer care.
Respiratory and Immunology: Products such as Fasenra, Breztri, Symbicort, Saphnelo, and Tezspire cater to a wide range of respiratory conditions, including COPD and asthma, emphasizing AstraZeneca's role in developing drugs that significantly improve the lives of people living with these conditions.
Covid-19 and Rare Diseases: The development and provision of Vaxzevria and Beyfortus for Covid-19, alongside Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for various rare diseases, reflect AstraZeneca's flexible approach towards global health crises and its dedication to addressing less common but equally critical health challenges.
Partnerships for Drug Development: AstraZeneca's collaborative efforts, such as with Neurimmune AG for the development of NI006 and BenevolentAI for drug discovery in systemic lupus erythematosus, highlight its strategy to leverage external expertise and technology to broaden its research and development capabilities, aiming to deliver innovative therapeutic options to patients faster.
